TSE:NRI - Nuvo Pharmaceuticals Stock Price, News, & Analysis

C$0.70
0.00 (0.00 %)
(As of 07/19/2019 04:00 PM ET)
Today's Range
C$0.70
Now: C$0.70
C$0.70
50-Day Range
C$0.60
MA: C$0.75
C$0.94
52-Week Range
C$0.60
Now: C$0.70
C$3.95
Volume2,000 shs
Average Volume8,203 shs
Market CapitalizationC$7.97 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Nuvo Pharmaceuticals Inc., a commercial healthcare company, produces and sells pharmaceutical products in the United States, Canada, and Europe. It offers Pennsaid, a topical pain product that is used to treat the signs and symptoms of osteoarthritis of the knee; Pennsaid 2%, a follow-on product to Pennsaid for the treatment of the pain of osteoarthritis of the knee; Heated Lidocaine/Tetracaine (HLT) Patch, a topical patch that provides local analgesia prior to painful needle procedures, such as dialysis, blood draws, and pediatric needles; and Resultz, an over-the-counter product intended to kill head lice and remove their eggs from hair. The company was formerly known as Nuvo Research Inc. and changed its name to Nuvo Pharmaceuticals Inc. in March 2016. Nuvo Pharmaceuticals Inc. was founded in 1983 and is headquartered in Mississauga, Canada.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-905-6736980

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$30.12 million
Cash FlowC$1.51 per share
Book ValueC$1.11 per share

Profitability

Miscellaneous

Employees97
Market CapC$7.97 million
Next Earnings Date8/1/2019 (Estimated)
OptionableNot Optionable

Receive NRI News and Ratings via Email

Sign-up to receive the latest news and ratings for NRI and its competitors with MarketBeat's FREE daily newsletter.

Nuvo Pharmaceuticals (TSE:NRI) Frequently Asked Questions

What is Nuvo Pharmaceuticals' stock symbol?

Nuvo Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "NRI."

How were Nuvo Pharmaceuticals' earnings last quarter?

Nuvo Pharmaceuticals Inc (TSE:NRI) issued its earnings results on Tuesday, May, 14th. The specialty pharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.21) by $0.02. The specialty pharmaceutical company earned $14.55 million during the quarter, compared to analysts' expectations of $13 million. View Nuvo Pharmaceuticals' Earnings History.

When is Nuvo Pharmaceuticals' next earnings date?

Nuvo Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, August 1st 2019. View Earnings Estimates for Nuvo Pharmaceuticals.

What is the consensus analysts' recommendation for Nuvo Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nuvo Pharmaceuticals in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Nuvo Pharmaceuticals.

Has Nuvo Pharmaceuticals been receiving favorable news coverage?

News coverage about NRI stock has been trending extremely negative recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Nuvo Pharmaceuticals earned a daily sentiment score of -4.6 on InfoTrie's scale. They also assigned media coverage about the specialty pharmaceutical company a news buzz of 8.0 out of 10, meaning that recent press coverage is very likely to have an effect on the company's share price in the immediate future. View News Stories for Nuvo Pharmaceuticals.

Who are some of Nuvo Pharmaceuticals' key competitors?

What other stocks do shareholders of Nuvo Pharmaceuticals own?

Who are Nuvo Pharmaceuticals' key executives?

Nuvo Pharmaceuticals' management team includes the folowing people:
  • Mr. Robert Paul Harris, Exec. Chairman (Age 64)
  • Mr. Jesse F. Ledger, Pres & CEO
  • Ms. Mary-Jane E. Burkett CPA-CA, HBA, VP & CFO
  • Ms. Katina K. Loucaides M.Sc., LL.B, VP, Corp. Sec. & Gen. Counsel
  • Mr. Calogero Lunetta MSc, VP of Manufacturing

How do I buy shares of Nuvo Pharmaceuticals?

Shares of NRI and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Nuvo Pharmaceuticals' stock price today?

One share of NRI stock can currently be purchased for approximately C$0.70.

How big of a company is Nuvo Pharmaceuticals?

Nuvo Pharmaceuticals has a market capitalization of C$7.97 million and generates C$30.12 million in revenue each year. Nuvo Pharmaceuticals employs 97 workers across the globe.View Additional Information About Nuvo Pharmaceuticals.

What is Nuvo Pharmaceuticals' official website?

The official website for Nuvo Pharmaceuticals is http://www.nuvopharmaceuticals.com/.

How can I contact Nuvo Pharmaceuticals?

Nuvo Pharmaceuticals' mailing address is 7560 Airport Rd Unit 10, MISSISSAUGA, ON L4T 4H4, Canada. The specialty pharmaceutical company can be reached via phone at +1-905-6736980.


MarketBeat Community Rating for Nuvo Pharmaceuticals (TSE NRI)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  67 (Vote Outperform)
Underperform Votes:  70 (Vote Underperform)
Total Votes:  137
MarketBeat's community ratings are surveys of what our community members think about Nuvo Pharmaceuticals and other stocks. Vote "Outperform" if you believe NRI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NRI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/19/2019 by MarketBeat.com Staff

Featured Article: Oversold

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel